Medications used in pediatric cystic fibrosis population

Detalhes bibliográficos
Autor(a) principal: Alves,Stella Pegoraro
Data de Publicação: 2018
Outros Autores: Frank,Márcia de Azevedo, Bueno,Denise
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Einstein (São Paulo)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082018000400201
Resumo: ABSTRACT Objective To describe the drug utilization profile used by pediatric cystic fibrosis patients. Methods A transversal study comprising the analysis of records and interviews with caregivers of pediatric patient in a reference center of Southern Brazil. We collected information about patients’ clinical condition, medication used and household therapy. Results Out of 78 patients participating in the study, prevailing characteristics were: female, self-declared white color, mutation F508del and countryside resident. Forty-three patients had health monitoring exclusively in the hospital’s outpatient division. We analyzed 509 prescribed medication (6.5 medication/patient). The caregiver acknowledged the correct indication in 83% of cases. Patients with pulmonary complications and diseases and/or comorbities related to the cystic fibrosis had an increased quantity of prescribed medication. Vitamins, pancreatic enzymes, hypertonic saline solution, dornase alpha, acid ursodesoxicolic and inhalation antibiotics were most commonly prescribed. Out of the sum of medication, 265 (52.1%) were registered in the Relação Nacional de Medicamentos Essenciais , 26.7% were registered in the basic component and 25.4% were registered in the specialized component of pharmaceutical assistance. Seventy-four interviewees informed difficulty in the acquisition of at least one prescribed medication. Most of the reports acknowledge the State Health Department as the place to find and receive medication for cystic fibrosis. Conclusion This study allowed reaching a deeper understanding about therapy, caring needed with patients with cystic fibrosis, highlighting to implement strategies that might contribute to enhance life quality and to execute the patients’ therapy plan.
id IIEPAE-1_6b0baae274f4a126b51b935a55d21fdd
oai_identifier_str oai:scielo:S1679-45082018000400201
network_acronym_str IIEPAE-1
network_name_str Einstein (São Paulo)
repository_id_str
spelling Medications used in pediatric cystic fibrosis populationDrug utilizationPharmaceutical servicesPharmaceutical preparationsCystic fibrosisChildCaregiversABSTRACT Objective To describe the drug utilization profile used by pediatric cystic fibrosis patients. Methods A transversal study comprising the analysis of records and interviews with caregivers of pediatric patient in a reference center of Southern Brazil. We collected information about patients’ clinical condition, medication used and household therapy. Results Out of 78 patients participating in the study, prevailing characteristics were: female, self-declared white color, mutation F508del and countryside resident. Forty-three patients had health monitoring exclusively in the hospital’s outpatient division. We analyzed 509 prescribed medication (6.5 medication/patient). The caregiver acknowledged the correct indication in 83% of cases. Patients with pulmonary complications and diseases and/or comorbities related to the cystic fibrosis had an increased quantity of prescribed medication. Vitamins, pancreatic enzymes, hypertonic saline solution, dornase alpha, acid ursodesoxicolic and inhalation antibiotics were most commonly prescribed. Out of the sum of medication, 265 (52.1%) were registered in the Relação Nacional de Medicamentos Essenciais , 26.7% were registered in the basic component and 25.4% were registered in the specialized component of pharmaceutical assistance. Seventy-four interviewees informed difficulty in the acquisition of at least one prescribed medication. Most of the reports acknowledge the State Health Department as the place to find and receive medication for cystic fibrosis. Conclusion This study allowed reaching a deeper understanding about therapy, caring needed with patients with cystic fibrosis, highlighting to implement strategies that might contribute to enhance life quality and to execute the patients’ therapy plan.Instituto Israelita de Ensino e Pesquisa Albert Einstein2018-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082018000400201einstein (São Paulo) v.16 n.4 2018reponame:Einstein (São Paulo)instname:Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)instacron:IIEPAE10.31744/einstein_journal/2018ao4212info:eu-repo/semantics/openAccessAlves,Stella PegoraroFrank,Márcia de AzevedoBueno,Deniseeng2018-10-31T00:00:00Zoai:scielo:S1679-45082018000400201Revistahttps://journal.einstein.br/pt-br/ONGhttps://old.scielo.br/oai/scielo-oai.php||revista@einstein.br2317-63851679-4508opendoar:2018-10-31T00:00Einstein (São Paulo) - Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)false
dc.title.none.fl_str_mv Medications used in pediatric cystic fibrosis population
title Medications used in pediatric cystic fibrosis population
spellingShingle Medications used in pediatric cystic fibrosis population
Alves,Stella Pegoraro
Drug utilization
Pharmaceutical services
Pharmaceutical preparations
Cystic fibrosis
Child
Caregivers
title_short Medications used in pediatric cystic fibrosis population
title_full Medications used in pediatric cystic fibrosis population
title_fullStr Medications used in pediatric cystic fibrosis population
title_full_unstemmed Medications used in pediatric cystic fibrosis population
title_sort Medications used in pediatric cystic fibrosis population
author Alves,Stella Pegoraro
author_facet Alves,Stella Pegoraro
Frank,Márcia de Azevedo
Bueno,Denise
author_role author
author2 Frank,Márcia de Azevedo
Bueno,Denise
author2_role author
author
dc.contributor.author.fl_str_mv Alves,Stella Pegoraro
Frank,Márcia de Azevedo
Bueno,Denise
dc.subject.por.fl_str_mv Drug utilization
Pharmaceutical services
Pharmaceutical preparations
Cystic fibrosis
Child
Caregivers
topic Drug utilization
Pharmaceutical services
Pharmaceutical preparations
Cystic fibrosis
Child
Caregivers
description ABSTRACT Objective To describe the drug utilization profile used by pediatric cystic fibrosis patients. Methods A transversal study comprising the analysis of records and interviews with caregivers of pediatric patient in a reference center of Southern Brazil. We collected information about patients’ clinical condition, medication used and household therapy. Results Out of 78 patients participating in the study, prevailing characteristics were: female, self-declared white color, mutation F508del and countryside resident. Forty-three patients had health monitoring exclusively in the hospital’s outpatient division. We analyzed 509 prescribed medication (6.5 medication/patient). The caregiver acknowledged the correct indication in 83% of cases. Patients with pulmonary complications and diseases and/or comorbities related to the cystic fibrosis had an increased quantity of prescribed medication. Vitamins, pancreatic enzymes, hypertonic saline solution, dornase alpha, acid ursodesoxicolic and inhalation antibiotics were most commonly prescribed. Out of the sum of medication, 265 (52.1%) were registered in the Relação Nacional de Medicamentos Essenciais , 26.7% were registered in the basic component and 25.4% were registered in the specialized component of pharmaceutical assistance. Seventy-four interviewees informed difficulty in the acquisition of at least one prescribed medication. Most of the reports acknowledge the State Health Department as the place to find and receive medication for cystic fibrosis. Conclusion This study allowed reaching a deeper understanding about therapy, caring needed with patients with cystic fibrosis, highlighting to implement strategies that might contribute to enhance life quality and to execute the patients’ therapy plan.
publishDate 2018
dc.date.none.fl_str_mv 2018-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082018000400201
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082018000400201
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.31744/einstein_journal/2018ao4212
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Instituto Israelita de Ensino e Pesquisa Albert Einstein
publisher.none.fl_str_mv Instituto Israelita de Ensino e Pesquisa Albert Einstein
dc.source.none.fl_str_mv einstein (São Paulo) v.16 n.4 2018
reponame:Einstein (São Paulo)
instname:Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
instacron:IIEPAE
instname_str Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
instacron_str IIEPAE
institution IIEPAE
reponame_str Einstein (São Paulo)
collection Einstein (São Paulo)
repository.name.fl_str_mv Einstein (São Paulo) - Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
repository.mail.fl_str_mv ||revista@einstein.br
_version_ 1752129909535277056